and will compare it to an historical control group of patients that have received drug-eluting stents through Medtronic’s prior clinical studies of its Resolute Onyx implant. Participants in ...

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

Medtronic has received investigational device ... DCB against drug-eluting stents using historical control data from the Resolute Onyx Clinical Program. For both cohorts, the primary endpoint ...